Radiation toxicity in prostate cancer patients
Abstract
Abstract
Prostate cancer (PC) is the most frequent male tumor, accounting for about one-third of all cancers in men. Because survival is often favorable regardless of therapy, treatment decisions may depend on therapy-specific health outcomes. The majority of men initially diagnosed with localized PC ultimately die with, rather than of, their disease. As a result, men who are diagnosed will live many years with the treatment's sequelae.
The major therapeutic strategies include radical prostatectomy or external beam radiotherapy. Radiotherapy is one of the curative treatment options. The tumor dose-response relationship has been studied and is widely accepted. The unsatisfactory local control with doses <70Gy led to dose escalation using highly precise radiotherapy techniques - three-dimensional conformal radiotherapy and intensity-modulated radiotherapy enabling the delivery of high radiation doses up to 74-78 Gy.
Bowel, rectal and urinary toxicities are the principal limiting factors in delivering a high dose. Acute symptoms include a change in bowel habits, urgency, and fecal incontinence. The most commonly reported late toxicities were chronic diarrhea, proctitis, or rectal bleeding. Several factors have been associated with increased gastrointestinal toxicity such as larger bowel volume receiving high doses, the patient's age, diabetes, and concomitant use of androgen deprivation therapy.
Bladder damage resulting from acute radiation toxicity is manifested as radiation cystitis (frequent urination and dysuric disorders). Smoking, previous abdominopelvic surgeries, and the use of diuretics significantly affect the occurrence of acute genitourinary toxicity grade ≥ 2. Risk factors for the development of late genitourinary complications are higher radiation dose, previous urinary problems, transurethral interventions, and acute genitourinary complications.
It is essential to strike a balance between the therapeutic benefits and radiotherapy side effects. Severe late complications significantly reduce the quality of life (QOL) of PC survivors. Early detection and proper evaluation of complications are especially important in increasing the patient's QOL.
References
Christensen K, Doblhammer G, Rau R, Vaupel JW. Ageing populations: the challenges ahead. Lancet. 2009;374(9696):1196–208.
U.S. Cancer Statistics Working Group. US cancer statistics: 1999–2009 incidence and mortality web-based report. Atlanta GA: USDHHS, CDC; 2013.
Bell KJ, Del Mar C, Wright G, Dickinson J, Glasziou P. Prevalence of incidental prostate cancer: A systematic review of autopsy studies. Int J Cancer. 2015;137(7):1749–57.
Siegel, R.L., Miller, K.D. and Jemal, A. (2018), Cancer statistics, 2018. CA: A Cancer Journal for Clinicians, 68: 7-30.
Wong MC, Goggins WB, Wang HH, Fung FD, Leung C, Wong SY, et al. Global Incidence and Mortality for Prostate Cancer: Analysis of Temporal Patterns and Trends in 36 Countries. Eur Urol. 2016;70(5):862–74.
Mottet N, van den Bergh RCN, Briers E, Cornford P, De Santis M, Fanti S, et al. Prostate Cancer. European Association of Urology.
Michaelson MD, Cotter SE, Gargollo PC, Zietman AL, Dahl DM, Smith MR. Management of complications of prostate cancer treatment. CA: a cancer journal for clinicians. 2008 Jul;58(4):196-213.
Hoffman KE, Voong KR, Levy LB, Allen PK, Choi S, Schlembach PJ, et al. Randomized Trial of Hypofractionated, Dose-Escalated, Intensity-Modulated Radiation Therapy (IMRT) Versus Conventionally Fractionated IMRT for Localized Prostate Cancer. J Clin Oncol. 2018;36(29):2943-2949.
Mynderse Lance A., Tristan Cummings, Michael A. King, Kent McDaniel, and Christopher Srnka. Mayo Clinic Essential Guide to Prostate Health. 2015.
Brady L, Combs S, Lu J. Target Volume Delineation for Conformal and Intensity-Modulated Radiation Therapy. Heidelberg: Springer; 2015.
Halperin EC, Wazer DE, Perez CA, Brady LW, editors. Perez and Brady’s principles and practice of radiation oncology. 7th edition. Philadelphia: Wolters Kluwer, 2018.
Toxicity criteria of the radiation therapy oncology group RTOG and the European organization for research and treatment of cancer EORTC. Int J Radiat Oncol Biol Phys 1995; 31:1341-6.
Serrano NA, Kalman NS, Anscher MS. Reducing rectal injury in men receiving prostate cancer radiation therapy: current perspectives. Cancer management and research. 2017;9:339.
Fajardo LF. The pathology of ionizing radiation as defined by morphologic patterns. Acta Oncol. 2005;44(1):13–22.
Valdagni R, Rancati T, Fioriono C et al. Development of set of nomograms to predict acute lower gastrointestinal toxicity for prostate cancer 3D-CRT. Int J Radiat Oncol Biol Phys. 2008; 74 (4):1065-73 36.
Stankovic V, Nikitovic M, Pekmezovic T, Pekmezovic D, Kisic Tepavcevic D, Stefanovic Djuric A, et al. Toxicity of the lower gastrointestinal tract and its predictive factors after 72Gy conventionally fractionated 3D conformal radiotherapy of localized prostate cancer. J BUON. 2016;21(5):1224-1232.
Vavassori V, Fiorino C, Rancati T et al. Predictor for rectal and intestinal acute toxicities during prostate cancer high-dose 3D-CRT: Results of a prospective multicenter study. Int J Radiat Oncol Biol Phys. 2007; 67 (5):1401- 1410 35.
World Endoscopy Organization. Radiation proctitis; 2012.
Peeters STH, Heemsbergen WD, Putten W LJ et al. Acute and late complications after radiotherapy for prostatae cancer: results of a multicentric randomized trial comparing 68Gy to 78Gy. Int J Radiat Oncol Biol Phys 2006; 61:1019-34.
Schmid MP, Pötter R, Bombosch V, Sljivic S, Kirisits C, Dörr W, Goldner G. Late gastrointestinal and urogenital side-effects after radiotherapy - Incidence and prevalence. Subgroup-analysis within the prospective Austrian - German phase II multicenter trial for localized prostate cancer. Radiotherapy and Oncology. 2012 Jul 1;104(1):114-8.
Barnett GC, De Meerleer G, Gulliford SL, Sydes MR, Elliott RM, Dearnaley DP. The impact of Clinical Factors on the Development of Late radiation toxicity: results from the Medical research Council RT01 Trial (ISRCTN47772397). Clinical oncology 2011; 23:613-624.
Mak RH, Hunt D, Shipley WU et al. Acute and Late Urinary Toxicity After Radiation Therapy in Men With and Without an Intact Prostate Gland: A Secondary Analysis of RTOG 9408 and 9601 Suggesting This Toxicity is Not Due to Bladder Injury. Int J Radiat Oncol Biol Phys 2012; 84(3), S14.
Michalski JM, Purdy JA, Winter K, Roach III M, Vijayakumar S, Sandler HM, Markoe AM, Ritter MA, Russell KJ, Sailer S, Harms WB. Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406. Int J Radiat Oncol Biol Phys. 2000 Jan 15;46(2):391-402.
Pinkawa M, Fischedick K, Asadpour B, Gagel B, Piroth MD, Nussen S, Eble MJ. Toxicity profile with a large prostate volume after external beam radiotherapy for localized prostate cancer. International Journal of Radiation Oncol Biol Physics. 2008 Jan 1;70(1):83-9.
Stankovic V, Džamic Z, Pekmezovic T, Kisic Tepavcevic D, Dozic M, Saric M, et al. Acute and Late Genitourinary Toxicity after 72 Gy of Conventionally Fractionated Conformal Radiotherapy for Localised Prostate Cancer: Impact of Individual and Clinical Parameters. Clin Oncol (R Coll Radiol). 2016;28(9):577-586.
Widmark A, Fransson P, Tavelin B. Self‐assessment questionnaire for evaluating urinary and intestinal late side effects after pelvic radiotherapy in patients with prostate cancer compared with an age‐matched control population. Cancer. 1994 Nov 1;74(9):2520-32.
Sandhu AS, Zelefsky MJ, Lee HJ, Lombardi D, Fuks Z, Leibel SA. Long-term urinary toxicity after 3-dimensional conformal radiotherapy for prostate cancer in patients with prior history of transurethral resection. International Journal of Radiation Oncol Biol Physics. 2000 Oct 1;48(3):643-7.
Lawton CA, Won M, Pilepich MV, et al. Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: analysis of RTOG studies 7506 and 7706. Int J Radiat Oncol Biol Phys 1991; 21:935.
Mathieu R, Arango JDO, Beckendorf V, Delobel J-B et al. Nomograms to predict late urinary toxicity after prostate cancer radiotherapy World J Urol 2014; 32:743-751.
Ballare A, Di Salvo M, Loi G, Ferrari G et al. Conformal radiotherapy of clinically localized prostate cancer: analysis of rectal and urinary toxicity and correlation with dose-volume parameters. Tumori 2009; 95:160-168.
Kalakota K, Liauw SL. Toxicity after external beam radiotherapy for prostate cancer: an analysis of late morbidity in men with diabetes mellitus. Urology. 2013 Jun;81(6):1196-201.